Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine.
Correale P, Tindara Miano S, Remondo C, Migali C, Rotundo MS, Macrì P, Tagliaferri P, Caraglia M, Gotti G, Francini G. Correale P, et al. Among authors: gotti g. Cancer Biol Ther. 2009 Mar 15;8(6):497-502. doi: 10.4161/cbt.8.6.7593. Epub 2009 Mar 15. Cancer Biol Ther. 2009. PMID: 19242101 Free article. Clinical Trial.
Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients.
Correale P, Remondo C, Carbone SF, Ricci V, Migali C, Martellucci I, Licchetta A, Addeo R, Volterrani L, Gotti G, Rotundo MS, Tassone P, Sperlongano P, Abbruzzese A, Caraglia M, Tagliaferri P, Francini G. Correale P, et al. Among authors: gotti g. Cancer Biol Ther. 2010 May 1;9(9):685-93. doi: 10.4161/cbt.9.9.11441. Cancer Biol Ther. 2010. PMID: 20697196 Free article. Clinical Trial.
Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients.
Correale P, Botta C, Basile A, Pagliuchi M, Licchetta A, Martellucci I, Bestoso E, Apollinari S, Addeo R, Misso G, Romano O, Abbruzzese A, Lamberti M, Luzzi L, Gotti G, Rotundo MS, Caraglia M, Tagliaferri P. Correale P, et al. Among authors: gotti g. Cancer Biol Ther. 2011 Jul 15;12(2):112-8. doi: 10.4161/cbt.12.2.15722. Epub 2011 Jul 15. Cancer Biol Ther. 2011. PMID: 21525780 Free article. Clinical Trial.
Chemo-hormone therapy of non-well-differentiated endocrine tumours from different anatomic sites with cisplatinum, etoposide and slow release lanreotide formulation.
Correale P, Sciandivasci A, Intrivici C, Pascucci A, Del Vecchio MT, Marsili S, Savelli V, Voltolini L, Di Bisceglie M, Guarnieri A, Gotti G, Francini G. Correale P, et al. Among authors: gotti g. Br J Cancer. 2007 May 7;96(9):1343-7. doi: 10.1038/sj.bjc.6603734. Epub 2007 Apr 17. Br J Cancer. 2007. PMID: 17437022 Free PMC article. Clinical Trial.
Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer.
Francini F, Pascucci A, Bargagli G, Francini E, Conca R, Miano ST, Martellucci I, Migali C, Gotti G, Fiaschi AI, Cozzolino A, Petrioli R. Francini F, et al. Among authors: gotti g. Int J Clin Oncol. 2011 Jun;16(3):264-9. doi: 10.1007/s10147-010-0179-x. Epub 2011 Jan 18. Int J Clin Oncol. 2011. PMID: 21240683 Clinical Trial.
The prognostic significance of proliferative indices in surgically resected IIIA-N2 non-small cell lung cancer after induction chemotherapy.
Corzani R, Luzzi L, Spina D, Voltolini L, Paladini P, Ghiribelli C, Ghisalberti M, Borrelli R, Meniconi F, Monaci N, Gotti G. Corzani R, et al. Among authors: gotti g. J Cardiovasc Surg (Torino). 2017 Oct;58(5):763-769. doi: 10.23736/S0021-9509.16.08232-X. Epub 2014 Apr 17. J Cardiovasc Surg (Torino). 2017. PMID: 24740119
118 results